SQZ Biotechnologies successfully lists its shares in an initial public offering (IPO). The biotech company receives backing from Global Health Sciences Fund, managed by Quark Venture LP and GF Securities. SQZ focuses on developing advanced biotechnology solutions, though specific details about its products or technology are not disclosed in the announcement.
Quark Venture, a Vancouver-based health-sciences investment fund, injects **$25 million** into a clinical-stage company developing novel infection treatments. The funding supports late-stage research aimed at addressing unmet medical needs in antimicrobial therapies. The company operates in the biotech sector, focusing on innovative solutions for bacterial and viral infections.
Quark Life Sciences secures a $656 million technology fund with significant investment backing from Chinese sources. The fund’s emergence has drawn attention due to its substantial capital and foreign investor ties. Details about the fund’s specific focus areas or portfolio companies remain undisclosed.
Quark Venture and GF Securities launch a **$500 million** venture fund focused on global health sciences innovation. The fund aims to support early-stage companies developing breakthrough solutions in healthcare. Both firms collaborate to bridge investment opportunities between North America and Asia.
Oct 2016BetaKitNews article
Global health sciences venture fund
Global Health Sciences Fund invests globally in biotechnology and health-technology companies, operating as a health-sciences investment fund.
